B. Pula, J. Mańko, Monika Pępek, T. Stoklosa, K. Hałaburda, Ewa Lech-Marańda, I. Hus
{"title":"Wenetoklaks w monoterapii przewlekłej białaczki limfocytowej przed powtórnym przeszczepieniem allogenicznych krwiotwórczych komórek macierzystych","authors":"B. Pula, J. Mańko, Monika Pępek, T. Stoklosa, K. Hałaburda, Ewa Lech-Marańda, I. Hus","doi":"10.5603/HEM.A2020.0010","DOIUrl":null,"url":null,"abstract":"Chronic lymphocytic leukemia (CLL) is the most common diagnosed leukemia in adults. Its clinical course is very heterogenous and only allogeneic hematopoietic stem cell transplantation (allo-HSCT) ensures cure of this disease. Introduction of venetoclax, an antagonist of the antiapoptotic BCL-2 protein, significantly improved patient outcome. Herein we present the use of venetoclax monotherapy as a bridging therapy before second allo-HSCT in a patient with relapsed and refractory CLL.","PeriodicalId":12837,"journal":{"name":"Haematologia","volume":"1 1","pages":"95-100"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/HEM.A2020.0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Wenetoklaks w monoterapii przewlekłej białaczki limfocytowej przed powtórnym przeszczepieniem allogenicznych krwiotwórczych komórek macierzystych
Chronic lymphocytic leukemia (CLL) is the most common diagnosed leukemia in adults. Its clinical course is very heterogenous and only allogeneic hematopoietic stem cell transplantation (allo-HSCT) ensures cure of this disease. Introduction of venetoclax, an antagonist of the antiapoptotic BCL-2 protein, significantly improved patient outcome. Herein we present the use of venetoclax monotherapy as a bridging therapy before second allo-HSCT in a patient with relapsed and refractory CLL.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
